Search | Clinical Trials Finder

Conditions: Early-phase Safety and PK Study of a Vaginal Gel
Interventions: YASO GEL, Placebo gel; Drug
Lead sponsor: Yaso Therapeutics Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Methamphetamine Abuse
Interventions: normal saline, ch-mAb7f9; Biological
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Asthma
Interventions: Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 9 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more

Conditions: Chronic Idiopathic Constipation
Interventions: plecanatide, Placebo; Drug · Other
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 100 more

Conditions: Type 2 Diabetes, End Stage Renal Disease
Interventions: Placebo, Sitagliptin; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions: Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more

Conditions: Gastric Cancer, Adenocarcinoma
Interventions: ramucirumab, Placebo, Best Supportive Care (BSC); Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Bakersfield, California • La Jolla, California • Redlands, California + 11 more

Conditions: Heartburn
Interventions: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Celiac Disease
Interventions: TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar; Drug · Dietary Supplement
Lead sponsor: Takeda; Industry
Eligibility: 12 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Paradise Valley, Arizona + 52 more

Conditions: Parkinson Disease
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy; Procedure · Other · Drug + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 242
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more

Conditions: Schizophrenia
Interventions: Oxytocin: 24IU - 168 IU, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions: Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires; Drug · Behavioral · Other
Lead sponsor: Brian Anderson, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Carotid Artery Diseases, Peripheral Arterial Disease
Interventions: Pegulicianine, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lennox Gastaut Syndrome
Interventions: ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo; Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 35 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more

Conditions: Knee Osteoarthritis
Interventions: Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more

Conditions: Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions: quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy; Drug · Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Lung Cancer, Non-Small Cell
Interventions: Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more

Conditions: Depression, Dementia
Interventions: Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hyperoxaluria
Interventions: Betaine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 45 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 8
States / cities: San Francisco, California • San Jose, California • Stanford, California + 5 more

Conditions: Alcoholism
Interventions: acamprosate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, Ceftriaxone, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Renal Insufficiency, Chronic
Interventions: 6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo; Drug · Other · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia

Search by objective public record fields.

FIH Lead-in Study of YASO GEL Followed by a Phase 1 Randomized, Double-blind Study to Assess Safety and Pharmacokinetics of YASO GEL

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

The Plecanatide Chronic Idiopathic Constipation (CIC) Study

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia

Ketamine-assisted Therapy for Advanced GI Cancer

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

Quetiapine for the Reduction of Cocaine Use

A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women

Acamprosate: Genes Associated With Response

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

Neurovascular Transduction During Exercise in Chronic Kidney Disease